2.985
Precedente Chiudi:
$3.00
Aprire:
$3
Volume 24 ore:
5,072
Relative Volume:
0.11
Capitalizzazione di mercato:
$252.83M
Reddito:
-
Utile/perdita netta:
$-29.64M
Rapporto P/E:
-6.9419
EPS:
-0.43
Flusso di cassa netto:
$-39.43M
1 W Prestazione:
-0.50%
1M Prestazione:
+10.15%
6M Prestazione:
+6.61%
1 anno Prestazione:
+19.40%
Alpha Tau Medical Ltd Stock (DRTS) Company Profile
Nome
Alpha Tau Medical Ltd
Settore
Industria
Telefono
-
Indirizzo
-
Confronta DRTS con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
DRTS
Alpha Tau Medical Ltd
|
2.985 | 254.10M | 0 | -29.64M | -39.43M | -0.43 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Alpha Tau Medical Ltd Stock (DRTS) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2023-12-15 | Iniziato | Citigroup | Buy |
2023-04-24 | Iniziato | H.C. Wainwright | Buy |
2022-04-14 | Iniziato | Cantor Fitzgerald | Overweight |
2022-04-08 | Iniziato | Piper Sandler | Overweight |
2022-04-04 | Iniziato | Citigroup | Buy |
Alpha Tau Medical Ltd Borsa (DRTS) Ultime notizie
Alpha Tau Medical to Present at Jefferies Healthcare Conference - TipRanks
Alpha Tau to Present at Jefferies Global Healthcare Conference - GlobeNewswire
Alpha Tau Medical Ltd. CFO Raphi Levy to Present at Jefferies Global Healthcare Conference on June 5, 2025 - Nasdaq
Alpha Tau Medical Reports Promising Q1 2025 Results - TipRanks
What is HC Wainwright’s Estimate for DRTS Q1 Earnings? - Defense World
Head to Head Review: Alpha Tau Medical (NASDAQ:DRTS) & DarioHealth (NASDAQ:DRIO) - Defense World
Alpha Tau Stock Rallies To 3-Month High On Smaller-Than-Feared Q1 Loss: Retail Sentiment Stays Bearish - MSN
Alpha Tau (DRTS) Advances Cancer Treatment Trials and Expansion Plans | DRTS Stock News - GuruFocus
Alpha Tau Medical Reports Q1 2025 Results and Major Clinical Advances - TipRanks
Alpha Tau reports Q1 EPS (12c), consensus (13c) - TipRanks
Alpha Tau Announces First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Alpha Tau Medical (DRTS) Projected to Post Earnings on Monday - Defense World
Alpha Tau Medical (NASDAQ:DRTSW) Shares Down 0.4% – Should You Sell? - Defense World
Radiopharmaceuticals Market Products and Applications Report 2025 | SPECT Radiopharmaceuticals Lead Diagnostic Market with 67% Share - GlobeNewswire Inc.
Alpha Tau Medical sets annual meeting for June 17 By Investing.com - Investing.com Nigeria
Alpha Tau Medical Schedules Annual Shareholder Meeting for June 2025 - TipRanks
Alpha Tau Medical sets annual meeting for June 17 - Investing.com
Alpha Tau Medical appoints new board member By Investing.com - Investing.com India
Alpha Tau Appoints Nadav Kidron to Board Following Strategic Investment - TipRanks
Alpha Tau Medical appoints new board member - Investing.com Australia
Alpha Tau Announces Appointment of Nadav Kidron to its Board of Directors - GlobeNewswire
Alpha Tau Medical And 2 Other Penny Stocks Worth Your Attention - Yahoo
Renaissance Technologies LLC Has $127,000 Position in Alpha Tau Medical Ltd. (NASDAQ:DRTS) - Defense World
Femasys (NASDAQ:FEMY) & Alpha Tau Medical (NASDAQ:DRTS) Critical Comparison - Defense World
Alpha Tau Medical Announces Participation in May 2025 Investor Conferences - TipRanks
Alpha Tau to Participate in May Investor Conferences - GlobeNewswire
Alpha Tau Reveals Next-Gen Cancer Treatment Updates: CFO Set for Two Exclusive Investor Events - Stock Titan
Alpha Tau Medical’s (DRTS) Buy Rating Reiterated at HC Wainwright - Defense World
HC Wainwright Lifts Earnings Estimates for Alpha Tau Medical - Defense World
Latham & Watkins Advises Alpha Tau Medical in US$36.9 Million Registered Direct Offering - Latham & Watkins LLP
Alpha Tau Medical Ltd: Strategic Investment and Promising Clinical Milestones Drive Buy Rating - TipRanks
Oramed Invests $36.9 Million In Alpha Tau For Strategic Growth - Finimize
Alpha Tau Medical (DRTS) Secures $36.9M in Direct Offering with Oramed Pharmaceuticals | DRTS Stock News - GuruFocus
Oramed invests $36.9 million in Alpha Tau cancer therapy By Investing.com - Investing.com
Alpha Tau Medical (DRTS) Secures $36.9M in Strategic Stock Sale - GuruFocus
Oramed Invests in Alpha Tau (DRTS) with Strategic Partnership | - GuruFocus
Alpha Tau Closes $36.9 Mln Offering And Forms Strategic Alliance With Oramed Pharmaceuticals - Nasdaq
Oramed Completes $36.9 Million Strategic Investment in Alpha Tau Medical - marketscreener.com
Alpha Tau enters strategic marketing alliance with Oramed - TipRanks
Alpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals - The Manila Times
Alpha Tau Announces Closing of $36.9 Million Registered - GlobeNewswire
Major Biotech Deal: Alpha Tau Medical Secures $36.9M Investment to Accelerate Cancer Treatment Innovation - Stock Titan
Oramed Closes $36.9M Strategic Investment in Alpha Tau Medical - citybiz
Alpha Tau Medical (NASDAQ:DRTSW) Shares Up 2.3% – Still a Buy? - Defense World
Comparing ICU Medical (NASDAQ:ICUI) and Alpha Tau Medical (NASDAQ:DRTS) - Defense World
Alpha Tau Medical Ltd Azioni (DRTS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):